

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **October 28, 2021**

**BIMI International Medical Inc.**

(Exact name of registrant as specified in its charter)

<b>Delaware</b> (State or other jurisdiction of incorporation)	<b>001-34890</b> (Commission File Number)	<b>02-0563302</b> (IRS Employer Identification No.)
<b>9th Floor, Building 2, Chongqing Corporation Avenue, Yuzhong District, Chongqing, P. R. China</b> (Address of principal executive offices)	<b>116000</b> (Zip Code)	

Registrant's telephone number, including area code: **(8604) 1182209211**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, \$0.001 par value	BIMI	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On October 28, 2021 BIM I International Medical Inc. (the “Company”) renewed the term of employment of the Company’s CEO Mr. Tiewei Song for one year and entered into a new employment agreement (the “Renewed Executive Employment Agreement”), effective October 1, 2021. Under the Renewed Executive Employment Agreement, Mr. Tiewei Song’s compensation shall consist of an annual base salary of \$1,000,000 in cash and an annual stock compensation of 1 million shares of the Company’s common stock. Other terms of the Renewed Executive Employment Agreement are substantially similar to the two-year executive employment agreement entered into by the Company and Mr. Song on October 1, 2019.

The Renewed Executive Employment Agreement is filed herewith as Exhibit 10.1.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

**Exhibit No Document**

---

10.1	<a href="#">Executive Employment Agreement dated October 28, 2021</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 1, 2021

**BIMI International Medical Inc.**

By: /s/ Tiewei Song

Name: Tiewei Song

Title: Chief Executive Officer